{"name":"Institut de Recherches Internationales Servier","slug":"institut-de-recherches-internationales-servier","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Bevacizumab control","genericName":"Bevacizumab control","slug":"bevacizumab-control","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"AG-120","genericName":"AG-120","slug":"ag-120","indication":"Acute myeloid leukemia (AML) with IDH1 mutation","status":"phase_3"},{"name":"Bevacizumab experimental","genericName":"Bevacizumab experimental","slug":"bevacizumab-experimental","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Temozolomide (TMZ)","genericName":"Temozolomide (TMZ)","slug":"temozolomide-tmz","indication":"Glioblastoma multiforme (newly diagnosed and recurrent)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Fixed [Per/Ind/Aml]","genericName":"Fixed [Per/Ind/Aml]","slug":"fixed-per-ind-aml","indication":"Hypertension","status":"phase_3"},{"name":"Free [Per/Ind + Aml]","genericName":"Free [Per/Ind + Aml]","slug":"free-per-ind-aml","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"Bevacizumab control","genericName":"Bevacizumab control","slug":"bevacizumab-control","phase":"phase_3","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with chemotherapy)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""},{"name":"AG-120","genericName":"AG-120","slug":"ag-120","phase":"phase_3","mechanism":"AG-120 is an isocitrate dehydrogenase 1 (IDH1) inhibitor that blocks the production of the oncometabolite 2-hydroxyglutarate in IDH1-mutant cancers.","indications":["Acute myeloid leukemia (AML) with IDH1 mutation","Myelodysplastic syndrome (MDS) with IDH1 mutation"],"catalyst":""},{"name":"Bevacizumab experimental","genericName":"Bevacizumab experimental","slug":"bevacizumab-experimental","phase":"phase_3","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Recurrent glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Fixed [Per/Ind/Aml]","genericName":"Fixed [Per/Ind/Aml]","slug":"fixed-per-ind-aml","phase":"phase_3","mechanism":"A fixed-dose combination of perindopril (ACE inhibitor), indapamide (thiazide-like diuretic), and amlodipine (calcium channel blocker) that reduces blood pressure through multiple complementary pathways.","indications":["Hypertension"],"catalyst":""},{"name":"Free [Per/Ind + Aml]","genericName":"Free [Per/Ind + Aml]","slug":"free-per-ind-aml","phase":"phase_3","mechanism":"A fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.","indications":["Hypertension"],"catalyst":""},{"name":"Temozolomide (TMZ)","genericName":"Temozolomide (TMZ)","slug":"temozolomide-tmz","phase":"phase_3","mechanism":"Temozolomide is an alkylating agent that methylates DNA at the O6 position of guanine, causing DNA strand breaks and cell death.","indications":["Glioblastoma multiforme (newly diagnosed and recurrent)","Anaplastic astrocytoma (recurrent)","Melanoma (metastatic)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQNjJpdG50VHNaMlU2VFhjWUZzOGt3Z1AwdHNvdFZLMVJRdjdkUE1uaEpxR0JmMDZTWjJtS0ZvdXoxLXlXUW03MlRqaU9Ya29zUFBzeXVlNFRNVjVSbUtjd29id0UwaVR4d2ViTTktdEttU0F5VTlLQzlwTEhBblFNdTI0MkVtNVpMSEpuZEc2WHdfMlQyb3pDdm0wcnU0M3UxOGpwNTJEV1RHYnZweUIyNmxnb0Q3dVl5WE5DSnRtcjBZYmVUYVl4b1ZOd2pTWEd2SERaV2pNV2h1eGYxTUpfM0oxV2lSbnhj?oc=5","date":"2026-03-19","type":"pipeline","source":"globenewswire.com","summary":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - globenewswire.com","headline":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3SWp6SnNJYV91aG42anhEX3lVMWVYQWRTbnY3ejZJd1IwRU5XSngycFEzNkdNSXF6a2tZazItUG12akF1VWl0VjRqM2N1d1FEQllESFR1YnhWdUZSdHNz?oc=5","date":"2025-01-06","type":"trial","source":"nature.com","summary":"MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial - nature.com","headline":"MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBWbkxzQVI0RW5OdUsweHAtS1IyMktsVjJrSWNFWWN2aUF6dlliZ1JtRExPanJWWXJzVVV1aXZOOU9IbXNJM1BuSENMLU1paTFvNjV4WG4wWndoY2U4WDJ3ZFVtRm5FemZnS3RKRVA5Q0hnR1pUNzdmbDN4X0h5RlE?oc=5","date":"2024-11-02","type":"pipeline","source":"Site Selection Magazine","summary":"French Pharma Giant Launches Research Institute - Site Selection Magazine","headline":"French Pharma Giant Launches Research Institute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRTk1WUd1djVnTS1LdDh4dHVxamhlNG1XamtSODhVQjlkYUNUM09peWxaSTcyTTU3X1ZSU0NIX0ZRWGpjVDdoeTRBcThXVzU0enNVSzZ0UGNnYmd6eXZDdmdaMTluaW9PV3dHNEw4aW1YM3FYU1dfVm51S3JiN282b3h3V1RLdHJVS1lSYW1CWHVDQmNFSGx1MDdIdFVIcU5QVHM1bzNBMFRLOERKUEFZQ1RwRlFOS2IzRWJj?oc=5","date":"2022-10-06","type":"pipeline","source":"Servier","summary":"The Research and Development Institute in Paris-Saclay - Servier","headline":"The Research and Development Institute in Paris-Saclay","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOMEpVMVY1d25xLTV1QkUtcUFkVk10WENtbkllaHNLNERIMEwxVDAzRld4alFmSXlZZlhqbHRFTzZMS0R4aWpXTldaaXQzTGlLV21mUi1NanFTOXBaeGdIb0RjUktYVXctRF9waTNZTnRKMHNVOHRxN0xRYkdTWnlPdWRn?oc=5","date":"2022-09-06","type":"pipeline","source":"Inria","summary":"Pharmaceutical research goes digital - Inria","headline":"Pharmaceutical research goes digital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYnh2eHc1c0NVQ2hmdVNzSHQ3dXljeVN5RGN4YlpvaUdGYWFvLVZYQjZNY0s1cUZsZzEyTlo0OHBUX2FsYktrLVB1a1lhUDg1dExNMGlRLTdVbzJ6WDQ2ZW45S00tRFpKelMtSVFOU3g5bVdFS1JHN0tuaDlBVU1sSGtOLVBuNXg5ZjlJZnQtQnBIaWZsUUw5M2R6Sm9mellRaFQ4bE9XMnMyU1FqbXA1amVDQ0Mzdk04UG9Qb0Y3WU5SbzRYQlNhS01pNXJ3RzVOeVREU2dXTm0wajItdmxNOWxwd0ppMGdrRTlLdWtNbUdFSkpMSzJLdA?oc=5","date":"2022-06-22","type":"pipeline","source":"Business Review","summary":"BR Interview | Michel Eschenbrenner, GM Servier Pharma Romania: Striving to improve quality of life in Romania - Business Review","headline":"BR Interview | Michel Eschenbrenner, GM Servier Pharma Romania: Striving to improve quality of life in Romania","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNWEdiVTNobmNpZmNGUFowMHFJOWVnNHU1b196MDdsRjhfVkx1VDhDdVVrUTFDRjBSR0ZnMHQxU2toWEg0V194M3V4eGw3Nl9sRjBpcnI5RGhnQjNNNU9wT2NRLWptT3JOMVFQM3BSU3JkcWtVdmJUV0htSEZIaHhTRnhRUmtWZw?oc=5","date":"2021-04-01","type":"pipeline","source":"CRISPR Medicine News","summary":"CMN Markets April 2021 (open access edition) - CRISPR Medicine News","headline":"CMN Markets April 2021 (open access edition)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNEJsMXBLQXp1bXA0amhLZ2lvdXFOaW9wRTNWX2NpSjF5MXdnb1h5ck5fSENuRWVkM2g0enk5VlBseE92ZkNfZzRHUE5iaGw1VHpRRmhmZHUxTFNtMUN6THRKNkNFM1Q5NTlyNGN6cHhFdXB1ODRYXzVjX0VMMkdzbll2SUlIcjkxY19wME5rcmpPTFhrbnVveXAwSjF2M29UeVNrLXFoelA4LXV5LVJyV0lkUTg5TWp2eHNnQlRPWFd1RVlFRG01Sg?oc=5","date":"2021-03-17","type":"earnings","source":"PR Newswire","summary":"CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results - PR Newswire","headline":"CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9XUHFNcG55TlFjUFZpeV96enVLZTVKSGRwQnZZdV9Eb2tOVl9pN3ZUYmY0SEw4ck5MeS1uVXdrdXF1MFpDbUpzMEVlUDVnUzJJSzExdUphUVlQd3loeXp4dGtyY2phMXQ2bVI4S2RQXzBOMTJfa2J2M1l4OHNUWW8?oc=5","date":"2020-08-04","type":"pipeline","source":"Chromatography Online","summary":"Mixed-Mode Chromatography—A Review - Chromatography Online","headline":"Mixed-Mode Chromatography—A Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1kbm1BeDlYYmZJYmdMSjRmdnNGcjhRYkFxQkRseDJ2VUNtRFFLOGNHWWFFbUh0dzhYaUJrZTFXa1REb05NRU1zeWZDMktIWUNwYkU4QmJrZVhCa0xtM0cxT3pMY290MVJlbWc?oc=5","date":"2019-11-26","type":"pipeline","source":"American Heart Association Journals","summary":"Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019) - American Heart Association Journals","headline":"Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNY0tjNGlRMmRPTTJLSE92djgxOWFkRHFFblR6VGl1S093VGJLYk9PUUJPZVBjblRFWTNvOEFzUWpNeGU4UmF5SGRSY0ctMVFqbUpZYTFmZ254ekpfeWtzeURkcVJJTW93TjhpUjM5MG02OTlVcFFlRmEwbVRqTFVVV01STzRxY2xtVjg2eldvLU1rYkpWOXc?oc=5","date":"2019-11-07","type":"pipeline","source":"Pharmaceutical Technology","summary":"Servier Paris-Saclay Research Institute, Paris, France - Pharmaceutical Technology","headline":"Servier Paris-Saclay Research Institute, Paris, France","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBfcU93TGswa1lWRUNzN1JlcmV4dTJuSlBhdVItN1B4azlBdWUxalNieVM4ZmY2Y0NkVWl6bUlyWG9xYWxqb19hRmVlRVlrY2F3NDcyN1NXY3NsR3dOYTZMZ3V5NVJ5M0RiWlhVUWFxNzkxVHgzZFlHZWppNA?oc=5","date":"2017-05-16","type":"regulatory","source":"European Pharmaceutical Review","summary":"Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research - European Pharmaceutical Review","headline":"Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":6},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}